Volume 14, Number 3—March 2008
Research
Epidemiology of Nontuberculous Mycobacteria in Patients without HIV Infection, New York City
Ethan E. Bodle*, Jennifer A. Cunningham*, Phyllis Della-Latta*, Neil W. Schluger*, and Lisa Saiman*
Table 3
Comparison of coexisting conditions and concomitant medications with body site of nontuberculous mycobacteria (NTM) disease, New York–Presbyterian Hospital, Columbia University Medical Center, New York, New York, 2000–2003
| Site of NTM disease | % Patients receiving concomitant medications (n = 79) |
||||
|---|---|---|---|---|---|
| Systemic steroids | Immunosuppressants | Chemotherapeutics | Immunomodulators | None | |
| Blood (n = 7) | 50 | 33 | 50 | 17 | 17 |
| Respiratory tract (n = 81) | 26 | 13 | 2 | 4 | 70 |
| Skin and soft tissue, surgical sites (n = 21) | 17 | 17 | 8 | 8 | 75 |
| All† | 25 | 15 | 6 | 5 | 66 |
*Defined as diabetes, chronic renal failure and/or rheumatologic disease.
†Includes 2 patients with disseminated disease following bone marrow transplantation, 1 patient with central nervous system disease receiving steroids, 1 patient with gastrointestinal disease, and 2 patients with lymph node disease/cancer.
